Olaparib, a PARP inhibitor, is approved for the treatment of human epidermal growth factor receptor 2 (HER2)–negative metastatic breast cancer (MBC) in germline (g)BRCA1/2 mutation carriers. Find out whether the results from this latest report will emphasize the value of molecular characterization (homologous recombination (HR)–related genes other than BRCA1/2) for treatment decisions in MBC.

Are traditional cytotoxic chemotherapies becoming a thing of the past? This study in the Journal of Clinical Oncology shows a move toward targeted agents, as a combination of obinutuzumab, ibrutinib, and venetoclax induced deep remissions in patients with treatment-naive or relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

We all have the same number of hours in the day. Things need to get done, and when you’re a physician, sometimes the day is gone before you feel like you even got started. Here are some tips and tricks to help streamline your schedule and improve your time management. You, your staff, and your family will appreciate the productivity and efficiency gains these tips could offer.

In this symposium preceding the ASH Annual Meeting on 12/4/20, the overall objective is to inform participants about emerging diagnostic and therapeutic aspects of bleeding and thrombotic disorders. The speakers will illustrate how costly and unnecessary biochemical, phenotypic, and genetic testing can be avoided in the participants’ practices while enhancing highest quality medical care.

In this article from MedPage Today, drinking green tea and coffee was associated with reduced all-cause mortality in Japanese patients with type 2 diabetes, especially those who drank both, researchers reported. In a cohort study that followed nearly 5,000 patients for approximately five years, the researchers found a dose-response relationship for both beverages.

In this article/podcast from KevinMD.com, the author fears that, after decades of progress in detecting, treating, and preventing many types of cancers, this nation could face a “cancer pandemic” in the next ten years as a result of this delay in routine screenings. These missed cancer screenings will likely result in delayed cancer diagnoses, recurrence of disease, and increases in cancer deaths.